Telix Pharmaceuticals Securities Class Action Reminder: Lead Plaintiff Deadline January 9, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Should l Buy TLX?
Source: Businesswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Telix Pharmaceuticals securities between February 21, 2025, and August 28, 2025, that the lead plaintiff deadline is January 9, 2026, allowing potential compensation without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Telix made materially false statements during the class period, overstating the progress of its prostate cancer therapeutic candidates and the quality of its supply chain, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, recovering over $438 million for investors in 2019 alone, showcasing its strong reputation in the field.
- Participation Instructions: Investors can join the class action by visiting the specified website or calling the toll-free number, emphasizing the importance of selecting qualified legal counsel to protect their interests, even though the class has not yet been certified.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TLX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TLX
About TLX
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Telix Pharmaceuticals Appoints New Non-Executive Director
- Board Expansion: Telix Pharmaceuticals announces the appointment of David Gill as a Non-Executive Director effective May 11, 2026, aimed at enhancing the board's succession planning and expansion to improve corporate governance.
- Extensive Industry Experience: With over 35 years in the life sciences sector, Gill has held senior management roles in various biopharmaceutical and medical device companies, and his deep capital markets expertise is expected to provide strategic advantages for Telix.
- Future Leadership Role: Gill is anticipated to succeed current Chair Mark Nelson, who will remain on the board as a Non-Executive Director, ensuring continuity and stability in the company's leadership.
- Global Business Development: Telix focuses on the development and commercialization of radiopharmaceuticals, and Gill's addition is expected to aid the company's expansion in global markets, particularly in addressing significant unmet medical needs in oncology and rare diseases.
See More
Telix Appoints New Director to Strengthen Governance
- Board Expansion: Telix Pharmaceuticals announces the appointment of David Gill as a Non-Executive Director effective May 11, 2026, aimed at enhancing the company's governance structure and paving the way for future succession planning.
- Extensive Industry Experience: With over 35 years in the life sciences sector, Gill has held CFO or President roles in multiple publicly traded companies, expected to bring deep capital market knowledge and corporate turnaround strategies to Telix.
- Strategic Leadership Change: Gill will succeed current Chair Mark Nelson, who will remain on the board as a Non-Executive Director, ensuring stability and continuity during the leadership transition for the company.
- Global Business Development: Telix focuses on the development and commercialization of radiopharmaceuticals, and Gill's addition is anticipated to aid the company's expansion in global markets, particularly in key regions like the U.S. and Europe.
See More
Talanx AG Reports Significant Growth in 2025 Performance
- Revenue Growth: Talanx AG achieved a 25% revenue increase in 2025, reaching approximately EUR 2.5 billion, demonstrating strong market performance and profitability, which is expected to further drive future investments and expansion.
- Dividend Increase: The company raised its dividend by 33% to EUR 3.60 per share, reflecting confidence in future performance while enhancing shareholder returns, potentially attracting more investor interest.
- Debt Management: By realizing EUR 860 million in bonds, Talanx AG strengthened its balance sheet, reducing debt leverage to 29.7%, which will enhance financial stability and support future growth.
- Net Asset Value Creation: The company created EUR 2.5 billion in net asset value, showcasing success in diversified investment portfolios and sound financial management, thereby enhancing market competitiveness and paving the way for potential acquisition opportunities.
See More
Telix Resubmits NDA for TLX101-Px to FDA
- NDA Resubmission: Telix Pharmaceuticals has resubmitted its New Drug Application for TLX101-Px to the U.S. FDA, including additional data requested, aiming to address the previous Complete Response Letter and expedite the approval process to meet significant unmet medical needs.
- Fast Track and Orphan Drug Designations: TLX101-Px has been granted Fast Track and Orphan Drug designations by the FDA, indicating its potential in treating recurrent or progressive gliomas, which could provide patients with a crucial imaging tool to enhance diagnosis and management.
- Clinical Practice Guidelines Recognition: The 18F-FET PET imaging technology is already included in international clinical practice guidelines for glioma imaging, yet there is currently no FDA-approved targeted amino acid PET agent available in the U.S., making TLX101-Px a significant market opportunity.
- Market Demand and Patient Benefit: With approximately 22,000 new cases of glioblastoma diagnosed annually in the U.S., Telix's TLX101-Px is expected to improve imaging diagnostics, aiding patients in managing this deadly disease and potentially enhancing survival rates and quality of life.
See More
Telix Pharmaceuticals Resubmits NDA for TLX101-Px Imaging Agent
- NDA Resubmission: Telix Pharmaceuticals has resubmitted its NDA for TLX101-Px to the FDA, aiming to recognize recurrent or progressive glioma, addressing additional data requested in the complete response letter from April 2025, demonstrating the company's proactive approach to regulatory challenges.
- Market Potential: With six cases of gliomas diagnosed per 100,000 people annually in the U.S., the drug presents significant market potential in addressing unmet medical needs, particularly among adult and pediatric patients.
- Financial Performance: Telix reported a revenue increase of 56% to $803.8 million in 2025 despite a pre-tax loss of $5.3 million, highlighting challenges in balancing revenue growth with cost control, while projecting future revenue guidance between $950 million and $970 million, reflecting optimism about market demand.
- European Market Application: Telix has filed a marketing authorization application for TLX101-Px in Europe, further expanding its market reach and indicating the company's strategy to seek growth opportunities globally, enhancing its competitive position in the biopharmaceutical sector.
See More
Telix Pharmaceuticals Resubmits TLX101-Px Drug Application
- New Drug Application Resubmission: Telix Pharmaceuticals announced on Sunday that it has resubmitted its new drug application for TLX101-Px, aiming to expedite market access for the drug, although specific approval timelines remain undisclosed, indicating the company's ongoing commitment to product development.
- Market Potential Assessment: If approved, TLX101-Px is expected to address unmet medical needs, particularly in oncology, potentially generating significant revenue growth for the company, which could enhance its market position.
- Continued R&D Investment: Telix's sustained investment in new drug development reflects its strategic positioning in the biopharmaceutical sector, particularly in precision medicine and personalized therapies, which may bolster its competitive edge in the market.
- Increased Investor Confidence: The news of the resubmission may boost investor confidence in Telix's future prospects, although market reactions are yet to be observed, this move could enhance the company's image in the capital markets.
See More
Telix Pharmaceuticals Appoints New Non-Executive Director
- Board Expansion: Telix Pharmaceuticals announces the appointment of David Gill as a Non-Executive Director effective May 11, 2026, aimed at enhancing the board's succession planning and expansion to improve corporate governance.
- Extensive Industry Experience: With over 35 years in the life sciences sector, Gill has held senior management roles in various biopharmaceutical and medical device companies, and his deep capital markets expertise is expected to provide strategic advantages for Telix.
- Future Leadership Role: Gill is anticipated to succeed current Chair Mark Nelson, who will remain on the board as a Non-Executive Director, ensuring continuity and stability in the company's leadership.
- Global Business Development: Telix focuses on the development and commercialization of radiopharmaceuticals, and Gill's addition is expected to aid the company's expansion in global markets, particularly in addressing significant unmet medical needs in oncology and rare diseases.
See More
Telix Appoints New Director to Strengthen Governance
- Board Expansion: Telix Pharmaceuticals announces the appointment of David Gill as a Non-Executive Director effective May 11, 2026, aimed at enhancing the company's governance structure and paving the way for future succession planning.
- Extensive Industry Experience: With over 35 years in the life sciences sector, Gill has held CFO or President roles in multiple publicly traded companies, expected to bring deep capital market knowledge and corporate turnaround strategies to Telix.
- Strategic Leadership Change: Gill will succeed current Chair Mark Nelson, who will remain on the board as a Non-Executive Director, ensuring stability and continuity during the leadership transition for the company.
- Global Business Development: Telix focuses on the development and commercialization of radiopharmaceuticals, and Gill's addition is anticipated to aid the company's expansion in global markets, particularly in key regions like the U.S. and Europe.
See More
Talanx AG Reports Significant Growth in 2025 Performance
- Revenue Growth: Talanx AG achieved a 25% revenue increase in 2025, reaching approximately EUR 2.5 billion, demonstrating strong market performance and profitability, which is expected to further drive future investments and expansion.
- Dividend Increase: The company raised its dividend by 33% to EUR 3.60 per share, reflecting confidence in future performance while enhancing shareholder returns, potentially attracting more investor interest.
- Debt Management: By realizing EUR 860 million in bonds, Talanx AG strengthened its balance sheet, reducing debt leverage to 29.7%, which will enhance financial stability and support future growth.
- Net Asset Value Creation: The company created EUR 2.5 billion in net asset value, showcasing success in diversified investment portfolios and sound financial management, thereby enhancing market competitiveness and paving the way for potential acquisition opportunities.
See More
Telix Resubmits NDA for TLX101-Px to FDA
- NDA Resubmission: Telix Pharmaceuticals has resubmitted its New Drug Application for TLX101-Px to the U.S. FDA, including additional data requested, aiming to address the previous Complete Response Letter and expedite the approval process to meet significant unmet medical needs.
- Fast Track and Orphan Drug Designations: TLX101-Px has been granted Fast Track and Orphan Drug designations by the FDA, indicating its potential in treating recurrent or progressive gliomas, which could provide patients with a crucial imaging tool to enhance diagnosis and management.
- Clinical Practice Guidelines Recognition: The 18F-FET PET imaging technology is already included in international clinical practice guidelines for glioma imaging, yet there is currently no FDA-approved targeted amino acid PET agent available in the U.S., making TLX101-Px a significant market opportunity.
- Market Demand and Patient Benefit: With approximately 22,000 new cases of glioblastoma diagnosed annually in the U.S., Telix's TLX101-Px is expected to improve imaging diagnostics, aiding patients in managing this deadly disease and potentially enhancing survival rates and quality of life.
See More
Telix Pharmaceuticals Resubmits NDA for TLX101-Px Imaging Agent
- NDA Resubmission: Telix Pharmaceuticals has resubmitted its NDA for TLX101-Px to the FDA, aiming to recognize recurrent or progressive glioma, addressing additional data requested in the complete response letter from April 2025, demonstrating the company's proactive approach to regulatory challenges.
- Market Potential: With six cases of gliomas diagnosed per 100,000 people annually in the U.S., the drug presents significant market potential in addressing unmet medical needs, particularly among adult and pediatric patients.
- Financial Performance: Telix reported a revenue increase of 56% to $803.8 million in 2025 despite a pre-tax loss of $5.3 million, highlighting challenges in balancing revenue growth with cost control, while projecting future revenue guidance between $950 million and $970 million, reflecting optimism about market demand.
- European Market Application: Telix has filed a marketing authorization application for TLX101-Px in Europe, further expanding its market reach and indicating the company's strategy to seek growth opportunities globally, enhancing its competitive position in the biopharmaceutical sector.
See More
Telix Pharmaceuticals Resubmits TLX101-Px Drug Application
- New Drug Application Resubmission: Telix Pharmaceuticals announced on Sunday that it has resubmitted its new drug application for TLX101-Px, aiming to expedite market access for the drug, although specific approval timelines remain undisclosed, indicating the company's ongoing commitment to product development.
- Market Potential Assessment: If approved, TLX101-Px is expected to address unmet medical needs, particularly in oncology, potentially generating significant revenue growth for the company, which could enhance its market position.
- Continued R&D Investment: Telix's sustained investment in new drug development reflects its strategic positioning in the biopharmaceutical sector, particularly in precision medicine and personalized therapies, which may bolster its competitive edge in the market.
- Increased Investor Confidence: The news of the resubmission may boost investor confidence in Telix's future prospects, although market reactions are yet to be observed, this move could enhance the company's image in the capital markets.
See More
